검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)) Stephan Grupp MD PhD·CD19 13 trials |
|---|---|
Overview Program | Autologous, humanized anti-CD19 CAR T cell therapy (huCART19) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | biomarker analyses (eg, circulating CAR T cells, cytokines, chemokines) |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.. Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity. In this study, we assessed the safety, … |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)) Stephan Grupp MD PhD·CD19 13 trials |
|---|---|
Overview Program | Autologous, humanized anti-CD19 CAR T cell therapy (huCART19) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | biomarker analyses (eg, circulating CAR T cells, cytokines, chemokines) |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.. Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity. In this study, we assessed the safety, … |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교